The Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies
A recent Science Direct publication highlights the development of generating SARS-CoV-2 nucleocapsid specific monoclonal antibodies to help supply new tools to specifically target SARS-CoV-2, the causative agent resulting in COVID-19. The study refers to nucleocapsid proteins, mBG86 and mBG17 antibody expression plasmids, available to purchase on our catalog, here. The plasmids are originally provided from